Following positive early-stage results from its once weekly amycretin obesity drug, Novo Nordisk saw its shares jump on Friday. The trial revealed an average 22% weight reduction in 125 overweight or obese patients after 36 weeks, with gastrointestinal side effects being the most common—mild to moderate in severity. Shares closed 7.13% higher, down from earlier gains of nearly 14% but still at their best single session since March 2024. Meanwhile, fellow Danish obesity drug maker Zealand Pharma saw its shares rise by 4.7%, while Eli Lilly dipped in premarket trading.
Amycretin targets the same hormones that Wegovy mimics—GLP-1 and amylin—and Novo is also developing an oral version called Ozempic, which showed a 13.1% weight loss after 12 weeks in early trials with mild to moderate side effects. The company’s executive vice president expressed optimism about the subcutaneous phase 1b/2a results for amycretin, noting its potential as a novel treatment option. Novo remains focused on advancing both its once weekly and oral formulations for obesity management.
Source: https://www.cnbc.com/2025/01/24/novo-nordisk-shares-pop-10percent-on-early-stage-weight-loss-drug-trial-results-.html